GFS Advisors, LLC

Position in NTLA — Intellia Therapeutics, Inc.

CIK 1427263 HOUSTON, TX

Position in NTLA

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$2,199

New position

Shares Held

130

first reported quarter

Ownership

0.000%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#297

of 327 holders

Holding Since

Jun 2026

1 quarter on record

Voting authority Sole 0% Shared 0% None 100%

Healthcare · as of Jun 30, 2026

GFS Advisors, LLC holds $62,285 across 5 Biotechnology names. NTLA ranks #4 (3.5% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	RXRX	Recursion Pharmaceuticals, Inc.	10,000	$36,700
2	MRNA	Moderna, Inc.	75,981	$11,345
3	REGN	Regeneron Pharmaceuticals, Inc.	18	$11,223
4	NTLA	Intellia Therapeutics, Inc. This page	130	$2,199
5	CRSP	CRISPR Therapeutics AG	15	$818

1 filing row on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$2,199	130	—	Shares	Sole	2026-08-13
No filing history on record for this holder in this stock.